Truist Securities Maintains Hold on Inari Medical, Lowers Price Target to $65
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Richard Newitter has maintained a 'Hold' rating on Inari Medical (NASDAQ:NARI) and lowered the price target from $70 to $65.
July 19, 2023 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Inari Medical's price target has been lowered from $70 to $65 by Truist Securities, while maintaining a 'Hold' rating.
The lowering of the price target by Truist Securities indicates a potential decrease in the stock's value. However, the 'Hold' rating suggests that the stock is expected to perform at the same level in the near term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100